Literature DB >> 35877198

The Clonal Relationship Between the Ductal and Lobular Components of Mixed Ductal-Lobular Carcinomas Suggested a Ductal Origin in Most Tumors.

Belén Pérez-Mies1,2,3,4, Tamara Caniego-Casas1,2,3, Irene Carretero-Barrio1,2,4, Michele Biscuola3,5, María A López-García3,5, David Hardisson3,6,7,8, Marta Rosas1,2, María J López Rodríguez2,9, Eva Cristóbal1,2, David Pizarro1,2, Juan M Rosa-Rosa1,2, José Palacios1,2,3,4.   

Abstract

The relationship between the ductal and lobular components of invasive ductolobular carcinomas (IDLC) has not been fully elucidated. In this study, the molecular alterations of both components were analyzed in a series of 20 IDLC that were selected, not only by morphologic criteria, but also by the loss of E-cadherin expression in the lobular component. We found that 80% of tumors shared alterations of driver genes in both components, being PIK3CA the most common alteration. In addition, 45% of IDLC carried CDH1 mutations in their lobular component that were absent in the ductal component. Fluorescent in situ hybridization analysis of the CDH1 gene excluded homozygous CDH1 loss as a frequent cause of E-cadherin loss in tumors without CDH1 mutations. In addition, no pathogenic mutations of catenin genes were detected in this series of tumors. In 25% of tumors, actionable mutations in PIK3CA , AKT1 , and ERBB2 were found in only 1 component. Altogether, our results confirm that most IDLC derive from invasive carcinoma of no special type, in which a population of cells lose E-cadherin and acquire a lobular phenotype. The frequency of CDH1 mutations in IDLC appears to be lower than in conventional invasive lobular carcinomas, suggesting the implication of alternative mechanisms of E-cadherin loss. Moreover, molecular heterogeneity between ductal and lobular areas suggests the need for molecular characterization of both components to guide targeted therapies.
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35877198      PMCID: PMC9561241          DOI: 10.1097/PAS.0000000000001936

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.298


  19 in total

1.  Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade.

Authors:  Otto Metzger-Filho; Arlindo R Ferreira; Rinath Jeselsohn; William T Barry; Deborah A Dillon; Jane E Brock; Ines Vaz-Luis; Melissa E Hughes; Eric P Winer; Nancy U Lin
Journal:  Oncologist       Date:  2018-12-05

2.  Clonal relationship between closely approximated low-grade ductal and lobular lesions in the breast: a molecular study of 10 cases.

Authors:  Patrick L Wagner; Naoki Kitabayashi; Yao-Tseng Chen; Sandra J Shin
Journal:  Am J Clin Pathol       Date:  2009-12       Impact factor: 2.493

3.  Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability.

Authors:  David Sarrió; Gema Moreno-Bueno; David Hardisson; Carolina Sánchez-Estévez; Mingzhou Guo; James G Herman; Carlos Gamallo; Manel Esteller; José Palacios
Journal:  Int J Cancer       Date:  2003-08-20       Impact factor: 7.396

4.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

Authors:  Antonio C Wolff; M Elizabeth Hale Hammond; Kimberly H Allison; Brittany E Harvey; Pamela B Mangu; John M S Bartlett; Michael Bilous; Ian O Ellis; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Lisa M McShane; Mitchell Dowsett
Journal:  Arch Pathol Lab Med       Date:  2018-05-30       Impact factor: 5.686

Review 5.  Invasive lobular carcinoma of the breast: the increasing importance of this special subtype.

Authors:  Amy E McCart Reed; Lauren Kalinowski; Peter T Simpson; Sunil R Lakhani
Journal:  Breast Cancer Res       Date:  2021-01-07       Impact factor: 6.466

Review 6.  Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors.

Authors:  Matthias Christgen; Gábor Cserni; Giuseppe Floris; Caterina Marchio; Lounes Djerroudi; Hans Kreipe; Patrick W B Derksen; Anne Vincent-Salomon
Journal:  Cancers (Basel)       Date:  2021-07-22       Impact factor: 6.639

7.  Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma.

Authors:  Matthias Christgen; Leonie Donata Kandt; Wiebke Antonopoulos; Stephan Bartels; Mieke R Van Bockstal; Martin Bredt; Maria Jose Brito; Henriette Christgen; Cecile Colpaert; Bálint Cserni; Gábor Cserni; Maximilian E Daemmrich; Raihanatou Danebrock; Franceska Dedeurwaerdere; Carolien Hm van Deurzen; Ramona Erber; Christine Fathke; Henning Feist; Maryse Fiche; Claudia Aura Gonzalez; Natalie D Ter Hoeve; Loes Kooreman; Till Krech; Glen Kristiansen; Janina Kulka; Florian Laenger; Marcel Lafos; Ulrich Lehmann; Maria Dolores Martin-Martinez; Sophie Mueller; Enrico Pelz; Mieke Raap; Alberto Ravarino; Tanja Reineke-Plaass; Nora Schaumann; Anne-Marie Schelfhout; Maxim De Schepper; Jerome Schlue; Koen Van de Vijver; Wim Waelput; Axel Wellmann; Monika Graeser; Oleg Gluz; Sherko Kuemmel; Ulrike Nitz; Nadia Harbeck; Christine Desmedt; Giuseppe Floris; Patrick Wb Derksen; Paul J van Diest; Anne Vincent-Salomon; Hans Kreipe
Journal:  J Pathol Clin Res       Date:  2021-12-10

8.  Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.

Authors:  Maggie C U Cheang; Stephen K Chia; David Voduc; Dongxia Gao; Samuel Leung; Jacqueline Snider; Mark Watson; Sherri Davies; Philip S Bernard; Joel S Parker; Charles M Perou; Matthew J Ellis; Torsten O Nielsen
Journal:  J Natl Cancer Inst       Date:  2009-05-12       Impact factor: 13.506

9.  Modified SureSelectQXT Target Enrichment Protocol for Illumina Multiplexed Sequencing of FFPE Samples.

Authors:  J M Rosa-Rosa; T Caniego-Casas; S Leskela; G Muñoz; F Del Castillo; P Garrido; J Palacios
Journal:  Biol Proced Online       Date:  2018-10-12       Impact factor: 3.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.